Nan Chi Wan
UCB Pharma (United Kingdom)(GB)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Protein Kinase Regulation and GTPase Signaling, Biochemical and Molecular Research, Asymmetric Synthesis and Catalysis, DNA and Nucleic Acid Chemistry
Most-Cited Works
- → The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer(2008)741 cited
- → Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941(2009)271 cited
- → Dual-recognition surface-enhanced Raman scattering(SERS)biosensor for pathogenic bacteria detection by using vancomycin-SERS tags and aptamer-Fe3O4@Au(2019)181 cited
- → Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer(2010)131 cited
- → Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor(2010)88 cited
- → Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform(2011)70 cited
- → Development of spike protein-based fluorescence lateral flow assay for the simultaneous detection of SARS-CoV-2 specific IgM and IgG(2021)55 cited
- → Design and Synthesis of New Templates Derived from Pyrrolopyrimidine as Selective Multidrug-Resistance-Associated Protein Inhibitors in Multidrug Resistance(2004)44 cited
- → Lithium Ephedrinate Mediated Aldol Reaction of Arylacetonitriles: Thermodynamic Control of Enantioselectivity(1998)34 cited
- → Scale-Up of a High Cell Density Continuous Culture with Pichia pastoris X-33 for the Constitutive Expression of rh-Chitinase(2001)33 cited